PureTech Health has launched Celea Therapeutics to advance its drug candidate deupirfenidone (LYT-100) targeting idiopathic pulmonary fibrosis (IPF) and other inflammatory lung diseases. Deupirfenidone, a chemically improved version of pirfenidone, demonstrated improved efficacy and tolerability in a Phase 2b trial. Celea is preparing for an FDA meeting by the third quarter to discuss Phase 3 trial design. PureTech will seek external funding to support development and commercialization.